Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.32 |
| ▸ | EYA2 | O00167 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11039366 | 0.98 | TDP1 (0.33) | TDP1EYA2APPACEFFAR3 | |
| SCHEMBL1419033 | 0.96 | TDP1 (0.32) | TDP1EYA2APPACEFFAR3 | |
| SCHEMBL786771 | 0.96 | TDP1 (0.32) | TDP1EYA2APPACEFFAR3 | |
| Hydrochloric Acid SCHEMBL10890767 | 0.94 | TDP1 (0.31) | TDP1EYA2APPACEFFAR3 | |
| Nitrilotriacetic Acid SCHEMBL10898452 | 0.92 | TDP1 (0.39) | TDP1EYA2APPACEADRA1A | |
| SCHEMBL3728136 | 0.79 | CHRM1 (0.33) | TDP1FFAR3ADRA1ADRD3SLC6A3 | |
| SCHEMBL957226 | 0.77 | FFAR3 (0.35) | TDP1EYA2APPACEFFAR3 | |
| SCHEMBL215964 | 0.77 | FFAR3 (0.35) | TDP1EYA2APPACEFFAR3 | |
| SCHEMBL20988159 | 0.75 | FFAR3 (0.36) | TDP1EYA2APPACEFFAR3 | |
| SCHEMBL1745549 | 0.74 | ADRA2A (0.32) | TDP1EYA2APPACEFFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8801962-B2 | Chelating agents and methods relating thereto | INNOSPEC LIMITED (GB) | 2014-08-12 | — | — | US | claimed |
| US-20120068113-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | INNOSPEC LIMITED (GB) | 2012-03-22 | — | — | US | claimed |
| EP-2389353-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | Innospec Limited (GB) | 2011-11-30 | — | — | EP | claimed |
| US-8039831-B2 | Electronic device containing semiconductor polymers and corresponding manufacturing process | MICRON TECHNOLOGY, INC. | 2011-10-18 | — | — | US | claimed |
| WO-2010084351-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | INNOSPEC LIMITED (GB) | 2010-07-29 | — | — | WO | claimed |
| US-8801962-B2 | Chelating agents and methods relating thereto | INNOSPEC LIMITED (GB) | 2014-08-12 | — | — | US | disclosed |
| US-20120068113-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | INNOSPEC LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| EP-2389353-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | Innospec Limited (GB) | 2011-11-30 | — | — | EP | disclosed |
| US-8039831-B2 | Electronic device containing semiconductor polymers and corresponding manufacturing process | MICRON TECHNOLOGY, INC. | 2011-10-18 | — | — | US | disclosed |
| WO-2010084351-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | INNOSPEC LIMITED (GB) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120068113-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | SLC30A5, AOC1, SLC25A13 | TDP1 1286/4885EYA2 2440/4885APP 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.